Geovax Awarded $3.6 Million Grant By U.S. Government For Its HIV/AIDS Vaccine Program


U.S Government Continues Support for Clinical Development of Adjuvanted Vaccine

Atlanta, GA (I-Newswire) August 16, 2011 - GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

This grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. Government. Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award.
This most recent annual award represents the fifth year's award, bringing the aggregate award to date to $19.6 million. GeoVax will utilize this funding to further production of its GM-CSF adjuvanted vaccine for planned human clinical trials.

"This award will allow us to maintain momentum on the successful development of our GM-CSF adjuvanted vaccine", said Harriet Robinson, Ph.D., Chief Scientific Officer of GeoVax and Program Director for the Award. "Depending on FDA submission schedules, we anticipate beginning a Phase 1 clinical trial within the next six months. The exciting thing about using the GM-CSF adjuvant is that it significantly increases prevention of infection. Without the adjuvant, our vaccine has been demonstrated to successfully control infection, but prevention of infection is the ultimate goal. There is widespread enthusiasm and desire for a vaccine that provides the promise for prevention of infection."

"We just had our annual External Advisory Board Meeting for our GM-CSF adjuvant project", said Robert McNally, Ph.D., President & CEO of GeoVax. "It was very productive with the outside experts being highly enthusiastic about the GM-CSF adjuvanted vaccine and very complimentary of the progress GeoVax has made."

About GeoVax
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and involves 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.






About The Investor Relations Group

A first-in-class online destination for investors, the public, and media interested in small-cap pub   More..lic companies.Less..

Contact Information

The Investor Relations Group
Janet Vasquez
11 Stone Street 3rd floor
10004
Phone : 212-825-3210

Tags:

AIDS   HIV   vaccine   GM-CSF   adjuvant  

Published in:

Medical > Infectious Diseases

Published On:

August 16, 2011

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.


Related Releases

Meds India Offers High Quality Anxiety Treatment Drugs At Affordable Prices
Meds India, a leading online pharmacy based in India is offering a variety of FDA approved anxiety-treatment medicines at extremely affordable rates.

The Life-Saving Oxy Gulls
Oxy Gulls is a compact and portable oxygen device for those who need immediate oxygen in order to survive.

Best Food to Help You Quit Smoking
Would you truly like to quit smoking? In the event that the response is yes, so now is the right time to expend more vegetables, abatement meat, and change your container of espresso with a glass of milk.

"Medical Crossover: Miami Surgeon Makes History Introducing An Instructional Course in Spanish."
A distinguished Cuban surgeon, by the name of Carlos J. Laverina, MD. Taught a course in Spanish for the first time in the history of one of the most prestige's annual meetings for the American Academy for Orthopedic Surgeons.

Oral Surgery Specialists Reveal Long-Term Dangers of Delaying Wisdom Tooth Extraction
Utah oral and maxillofacial surgery practice spreads awareness about the grave effects of neglecting oral health